U.S. Markets closed

Ambrx Biopharma Inc. (AMAM)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
13.91+0.61 (+4.59%)
At close: 3:58PM EDT
13.85 -0.06 (-0.43%)
After hours: 04:00PM EDT

Ambrx Biopharma Inc.

10975 North Torrey Pines Road
La Jolla, CA 92037
United States

Full Time Employees70

Key Executives

NameTitlePayExercisedYear Born
Dr. Feng TianPres, CEO & ChairmanN/AN/A1968
Ms. Yumei Zhang CPA, M.B.A.VP of Fin.N/AN/AN/A
Dr. Joy Yan M.D., Ph.D.Chief Medical OfficerN/AN/A1980
Mr. Simon J. Allen B.Sc., M.B.A., MBAChief Bus. OfficerN/AN/A1968
Dr. Sukumar Sakamuri Ph.D.VP & Head of ChemistryN/AN/AN/A
Dr. Shawn Shao-Hui ZhangSr. VP of R&D Operations and Ambrx ChinaN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc., Sino Biopharmaceutical Co., Ltd., University of California, BeiGene, Ltd., The Scripps Research Institute and The California Research Institute of Biomedical Research, AbbVie Inc., Astellas Pharma Inc., and Elanco Animal Health. Ambrx Biopharma Inc. was founded in 2003 and is based in La Jolla, California.

Corporate Governance

Ambrx Biopharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.